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Abstract
Aims: We performed a propensity score matched analysis to explore whether TiNOX stents are superior to 
paclitaxel- (PES) and sirolimus-eluting stents (SES) in routine clinical practice.
Methods and results: A total of 1,607 patients undergoing implantation of SES, PES or TiNOX stents were 
prospectively entered into a stent registry and followed up for three years. Using propensity score matching, 
we compared clinical outcome among 319 pairs of patients treated with TiNOX stents or SES and 337 pairs 
of patients treated with TiNOX stents or PES. The primary outcome MACE, a composite of death, myocar-
dial infarction, and target vessel revascularisation occurred in 20% of patients with TiNOX stents, 19% of 
patients with SES and 23% of patients with PES at 3-years. The hazard ratio was 1.00 comparing TiNOX 
stents with SES (95% CI 0.69-1.45, p=1.00), and 0.95 comparing TiNOX stents with PES (95% CI 0.66-1.36, 
p=0.78).
Conclusions: We did not find evidence to suggest superiority of TiNOX stents over SES or PES. In view of 
similar clinical outcomes, but with the reduced duration of dual antiplatelet therapy used with the TiNOX 
stent, we suggest that TiNOX stents may be an alternative to drug-eluting stents in patients unsuitable for 
long-term dual antiplatelet therapy.
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Abbreviations
TiNOX titanium-nitride-oxide
DES drug-eluting stent(s)
PES paclitaxel-eluting stent(s)
SES sirolimus-eluting stent(s)
MACE major adverse cardiac event
MI myocardial infarction
TLR target lesion revascularisation
TVR target vessel revascularisation
PCI percutaneous coronary intervention
Introduction
Passive stent coating with titanium-nitride-oxide (TiNOX) has been 
shown to reduce platelet adhesion and fibrinogen binding in vitro and 
to reduce neointimal hyperplasia in the porcine restenosis model1. In 
a randomised clinical trial, the TiNOX trial, TiNOX was found supe-
rior in terms of late lumen loss and restenosis, with fewer target 
lesion revascularisations (TLR) compared with stainless steel stents 
of otherwise identical design2. The beneficial effects of TiNOX stents 
were attributed to its high corrosion resistance and excellent biocom-
patibility. In vitro and in vivo studies showed rapid vascular healing 
without signs of inflammatory reactions and granuloma formation3,4. 
Furthermore, TiNOX stents were found to have NO-molecules on the 
coating surface5, which appear to have antiproliferative and anti-
aggregatory properties. In a long-term follow-up of the TiNOX trial, 
there was a 59% relative risk reduction of major adverse cardiac 
events (MACE) at 3-years compared with stainless steel stents (95% 
CI 4% to 82%)6. A recent randomised trial comparing TiNOX with a 
zotarolimus-eluting stent, a newer generation drug-eluting stent, sug-
gested that TiNOX was inferior in terms of angiographic late loss and 
binary restenosis7. The only available long-term clinical comparison 
of TiNOX stents with drug-eluting stents, a recently published obser-
vational study with propensity score adjustment, found a robust 52% 
relative risk reduction of MACE at 3-years as compared with PES 
(95% CI 17 to 72%)8. We performed propensity-matched analyses 
nested in a registry to explore whether TiNOX stents are indeed supe-
rior to PES or to sirolimus-eluting stents (SES) in routine clinical 
practice at three years.
Methods
PAtiEntS
All patients undergoing implantation of coronary stents at Bern Uni-
versity Hospital, Switzerland are entered into a dedicated registry. 
Between May 2004 (after completion of SIRTAX study) and February 
2005, 542 consecutive patients underwent treatment with at least one 
SES (Cypher™; Cordis, Miami Lakes, FL, USA) and 507 consecutive 
patients underwent treatment with at least one PES (Taxus™, Boston 
Scientific Corporation, Natick, MA, USA). Between July 2005 and 
April 2007, 558 consecutive patients underwent treatment with TiNOX 
stents (Titan 2 Cross Max™; Hexacath, Paris, France). The 3-year 
follow-up was performed between February and June 2008 in patients 
who underwent implantation of SES or PES and between September 
2009 and February 2010 in patients with TiNOX stents.
Eligible patients had a history of stable angina or acute coronary 
syndrome and presented with at least one lesion with a diameter ste-
nosis >50% in a vessel with a reference vessel diameter (RVD) 
between 2.25 mm and 4.00 mm suitable for stent implantation. 
Acute coronary syndrome included unstable angina according to 
Braunwald’s definition, non-ST-elevation myocardial infarction 
and ST-elevation myocardial infarction. There were no limitations 
on the number of treated lesions and vessels, or lesion length. 
Exclusion criteria were a known allergy to acetylsalicylic acid, 
thienopyridines, heparin, stainless steel, titanium-nitride-oxide, 
sirolimus, paclitaxel, or contrast agents, previous implantation of 
another DES, and patients with terminal illness. The study com-
plied with the Declaration of Helsinki regarding investigation in 
humans and was approved by the institutional ethics committee of 
Bern, Switzerland. All patients provided written informed consent.
TiNOX stents were available in diameters of 2.25 to 4.0 mm and in 
lengths of 8 to 28 mm; SES were available in diameters of 2.25 to 
3.5 mm and in lengths of 8 to 33 mm; PES were available in diame-
ters of 2.25 to 3.5 mm and in lengths of 8 to 32 mm. Only patients 
who received a single type of study stent during the index procedure 
were eligible. Balloon angioplasty and stent implantation were per-
formed according to standard techniques. Direct stenting was permit-
ted. Full lesion coverage was attempted by implantation of one or 
multiple stents. Before, or at the time of the procedure, all patients 
were treated with at least 100 mg acetylsalicylic acid, a 300 mg load-
ing dose of clopidogrel and unfractionated heparin in a dose of 
5000 U or 70-100 U/kg. Glycoprotein IIb/IIIa antagonists were used 
at the discretion of the operator. A 12-lead electrocardiogram was 
obtained after the procedure prior to discharge. Creatine kinase (CK), 
CK-MB, and troponin I were assessed at least once after the proce-
dure and repeated in case of laboratory abnormalities. All patients 
were discharged on acetylsalicylic acid 100 mg daily indefinitely and 
clopidogrel 75 mg daily for an intended duration of at least one 
month in stable and nine months in ACS patients in the TiNOX group 
and at least 12 months in the SES or PES group. However, the dura-
tion of dual antiplatelet therapy was at the discretion of the interven-
ing physicians and may be lower than nine months in some of the 
ACS patients receiving a TiNOX stent depending on the individual 
appraisal of the bleeding risk and the classification of the ACS (unsta-
ble versus non-ST-elevation MI versus ST-elevation MI).
Study	endpoIntS	And	defInItIonS
The primary outcome was MACE as the composite of death over-
all, myocardial infarction (MI) or target vessel revascularisation 
(TVR). Secondary outcomes were death overall, TVR, TLR, MI 
and definite stent thrombosis. A target lesion revascularisation was 
defined as a repeated revascularisation (percutaneous or surgical) 
based on a stenosis within the stent or within the 5 mm borders 
proximal or distal to the stent. The diagnosis of MI was established 
whenever new Q-waves of at least 0.4 seconds duration in at least 
two contiguous leads appeared on the electrocardiogram with an 
elevated creatine kinase MB fraction level, or in the absence of 
pathologic Q-waves, an elevation in creatine kinase levels to more 
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than twice the upper limit of normal and an elevated creatine kinase 
MB or troponin I level. Definite stent thrombosis was defined 
according to the definitions provided by the Academic Research 
Consortium9. Repeat angiography was only clinically driven by 
symptoms or signs suggestive of myocardial ischaemia, since 
patients were not encouraged for routine repeat angiograms. All 
clinical events were adjudicated by two independent cardiologists 
blinded for the stent type. In case of disagreement, a third cardiolo-
gist was consulted for the final decision.
Baseline characteristics were defined as follows: patients were 
defined as diabetics whenever oral antidiabetic or insulin treatment 
was prescribed on a regular basis prior to the index hospitalisation. 
Renal failure was defined as creatinine serum level of >150 µmol/l. 
Smoking was defined as current smoking (at least six cigarettes per 
day). Bleeding disorder was defined as patients with a history of a 
clinically relevant gastrointestinal, urogenital or intracranial haem-
orrhage. Alcoholism was defined as chronic consumption of more 
than 30 g per day for men and more than 20 g per day for women.
StAtIStIcAl	AnAlySIS
These were two propensity-matched superiority analyses. Sample 
size considerations were based on the recently published long-term 
follow-up of an observational study comparing TiNOX stents with 
PES, which found an approximate relative risk reduction for the 
composite of cardiac death, MI, or TVR of 50% in favour of TiNOX 
stents at an event rate of 24% in the PES group at three years8. In the 
absence of additional clinical evidence, we assumed the same rela-
tive risk reduction for our pre-specified primary endpoint of MACE, 
defined as the composite of death overall, MI, or TVR, in TiNOX 
stents compared with either of the two types of DES (PES or SES). 
A sample size of 320 matched pairs would provide greater than 
90% power to detect a relative risk of 0.50 in favour of TiNOX 
stents over PES or SES at a two-sided a of 0.025 after Bonferroni 
correction. Assuming that two-thirds of patients treated with 
TiNOX stents could be matched to patients treated with any of the 
two drug-eluting stents, approximately 500 patients in each group 
were necessary for the present analysis.
Baseline characteristics before and after matching are reported as 
means and standard deviations for continuous and absolute numbers 
and percentages for categorical variables. Baseline characteristics 
between the TINOX, SES, and PES patients were compared using an 
unpaired t-test and one-way analysis of variance as appropriate for 
comparisons of continuous variables between two and three groups, 
and a chi-square test for categorical variables. Then, we used propen-
sity-score matching to account for differences in baseline character-
istics between groups. The propensity scores for receiving TiNOX 
stents rather than SES or PES were estimated using a logit model 
with age, gender, and the following covariates associated at p<0.1 in 
a multivariable model as independent variables: diabetes, smoking, 
acute coronary syndrome (ACS), low left ventricular ejection frac-
tion of <50%, multivessel disease, small vessel disease (diameter 
≤2.75 mm), bleeding disorder, planned staged surgery within the next 
six months, and obligation to use Coumadin.
In order to assure comparable groups, the assumption of common 
support was applied, which indicates that patients with the same 
propensity score have a non-zero probability of receiving either 
TiNOX or one of the drug-eluting stents10. We estimated the 
Epanechnikov kernel probability densities of the propensity scores 
of the TiNOX and the drug-eluting stent groups based on propen-
sity score increments of 0.04. Observations with a propensity score 
>0.5 were then dropped, since the probability density of the propen-
sity score of the TiNOX group definitely dropped below a pre-spec-
ified cut-off value of 0.4 at this point. Then, we performed a 1:1 
nearest-neighbour calliper matching in a range of ±0.05 on the pro-
pensity score without replacement. The pool of patients who under-
went implantation of a TiNOX stent was used twice, once for the 
comparison with SES and once for the comparison with PES. For 
each pair, we ensured equal follow-up times by discarding observa-
tion time in patients treated with SES or PES extending beyond the 
follow-up duration of corresponding patients receiving TiNOX 
stents and vice versa. We used Cox proportional hazards models 
that accounted for the 1:1 matching to calculate hazard ratios of all 
primary and secondary outcomes comparing TiNOX with SES and 
TiNOX with PES over the entire follow-up time of up to three years 
(primary time-point), and up to 30 days. In a sensitivity analysis, 
we additionally adjusted for all procedural characteristics and dis-
charge medications. All p-values and 95% confidence intervals are 
two-sided. All analyses were done in Stata version 11 (StataCorp 
LP, College Station, TX, USA).
Results
A total of 558 consecutive patients underwent PCI of at least one 
lesion with TiNOX coated stents (total 882 stents), 542 patients 
with SES (916 stents), and 507 patients with PES (891 stents). 
Table 1 presents a comparison of patients before propensity score 
matching. Patients with TiNOX stents were older, had more often 
diabetes, a low left ventricular ejection fraction (EF), bleeding dis-
order, staged surgery within the next six months and an obligation 
to use Coumadin, had less often small vessel disease and were less 
frequently smoking compared with patients treated with SES or 
PES. The three groups were similar in terms of gender, hyperten-
sion, renal impairment, acute coronary syndrome, multivessel dis-
ease and alcoholism. Out of 1,607 patients, 1,521 (95%) completed 
planned follow-up up to three years: 523 patients receiving TiNOX 
stents (95%), 508 patients receiving SES (94%), and 481 patients 
treated with PES (95%).
Of patients treated with TiNOX stents, 319 could be matched 
with 319 patients treated with SES, and 337 patients treated with 
TiNOX stents could be matched with 337 patients treated with PES. 
Table 2 shows baseline characteristics after matching. All baseline 
variables were well balanced in both matched datasets (TiNOX vs. 
SES and TiNOX vs. PES). Table 3 presents a comparison of proce-
dural characteristics and discharge medication between stent types 
after matching. In general, procedural characteristics suggested 
a higher complexity in patients treated with drug-eluting stents, 
who had more stents implanted, a higher total stent length, smaller 
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Table 1. Baseline characteristics before propensity score matching.
TiNOX SES PES
p-value
Total 558 542 507
Age, years (mean±SD) 66.5±12.0 63.2±11.7 65.3±11.4 <0.001
Male sex (n [%]) 432 (77.4) 429 (79.2) 371 (73.2) 0.06
Diabetes (n [%]) 134 (24.0) 91 (16.8) 89 (17.6) 0.004
Hypertension (n [%]) 299 (53.6) 275 (50.7) 268 (52.9) 0.62
Renal impairment (n [%]) 31 (5.6) 19 (3.5) 15 (3.0) 0.07
Smoking (n [%]) 258 (46.2) 300 (55.4) 257 (50.7) 0.01
Stable angina pectoris (n [%]) 247 (44.3) 266 (49.1) 237 (46.8) 0.28
Acute coronary syndrome (n 
[%]) 311 (55.7) 276 (50.9) 270 (53.3) 0.28
ST-elevation MI (n [%]) 173 (31.0) 152 (28.2) 145 (28.6) 0.54
Low left ventricular EF (<50%) 
(n [%]) 214 (38.4) 142 (26.2) 126 (24.9) <0.001
Multivessel disease (n [%]) 368 (66.0) 355 (65.5) 338 (66.7) 0.92
Small vessel disease (n [%]) 185 (33.2) 250 (46.1) 202 (39.8) <0.001
Alcoholism (n [%]) 12 (2.2) 9 (1.7) 8 (1.6) 0.75
Bleeding disorder (n [%]) 10 (1.8) 1 (0.2) 0 (0) <0.001
Staged surgery within next 
6 months (n [%]) 87 (15.6) 9 (1.7) 11 (2.2) <0.001
Obligation to use Coumadin  
(n [%]) 135 (24.2) 43 (7.9) 40 (7.9) <0.001
Values are expressed in n (%) or mean ± SD. Two-sided p-values were calculated 
using a chi-square test for categorical variables and a one way analysis of variance 
for continuous variables. EF: ejection fraction
Table 2. Baseline characteristics after propensity score matching.
tinOX SES
p-value
tinOX PES
p-value
total 319 319 337 337
Age, years (mean±SD) 63.8±12.0 64.3±12.0 0.65 64.1±12.0 64.7±11.8 0.53
Male sex (n [%]) 247 (77.4) 255 (79.9) 0.44 262 (77.7) 257 (76.3) 0.65
Diabetes (n [%]) 54 (16.9) 53 (16.6) 0.92 62 (18.4) 66 (19.6) 0.69
Hypertension (n [%]) 165 (51.7) 166 (52.0) 0.94 171 (50.7) 168 (49.9) 0.82
Renal impairment (n [%]) 14 (4.4) 13 (4.1) 0.84 14 (4.2) 12 (3.6) 0.69
Smoking (n [%]) 157 (49.2) 172 (53.9) 0.24 165 (49.0) 167 (49.6) 0.88
Stable angina pectoris (n [%]) 141 (44.2) 149 (46.7) 0.53 143 (42.4) 133 (39.5) 0.43
Acute coronary syndrome (n [%]) 178 (55.8) 170 (53.3) 0.53 194 (57.6) 204 (60.5) 0.43
ST-elevation MI (n [%]) 102 (32.0) 98 (30.8) 0.75 113 (33.5) 109 (32.3) 0.74
Low left ventricular EF (<50%) (n [%]) 98 (30.7) 97 (30.4) 0.93 105 (31.2) 102 (30.3) 0.80
Multivessel disease (n [%]) 206 (64.6) 206 (64.6) 1.00 217 (64.4) 219 (65.0) 0.87
Small vessel disease (n [%]) 116 (36.4) 109 (34.2) 0.56 120 (35.6) 109 (32.3) 0.37
Alcoholism (n [%]) 6 (1.9) 3 (0.9) 0.31 6 (1.8) 5 (1.5) 0.76
Bleeding disorder (n [%]) 0 (0) 0 (0) 1.00 0 (0) 0 (0) 1.00
Staged surgery within next 6 months (n [%]) 0 (0) 0 (0) 1.00 0 (0) 0 (0) 1.00
Obligation to use Coumadin (n [%]) 5 (1.6) 10 (3.1) 0.19 9 (2.7) 12 (3.6) 0.51
Values are expressed in n (%) or mean ±SD. Two-sided p-values were calculated using a chi-square test for categorical variables and an unpaired t-test 
for continuous variables. EF: ejection fraction
stent diameters, more saphenous vein graft interventions and a 
higher use of glycoprotein IIb/IIIa antagonists. Medical co-inter-
ventions, including beta blockers, ACE inhibitors and statins, were 
more frequent in patients who underwent implantation of a TiNOX 
stent. Median length of clopidogrel prescription was three months 
in patients treated with TiNOX (mean: 6.7 months, range: 0-36 
months) and 12 months in patients treated with SES or PES (mean: 
11.0 months, range: 0-36 months).
Table 4 presents all clinical outcomes for the matched groups 
(TiNOX vs. SES and TiNOX vs. PES) up to 30 days and up to three 
years. Kaplan-Meier curves are shown in Figure 1. The primary 
outcome MACE – the composite of death overall, MI, and TVR– 
occurred in 20% of patients with TiNOX stents, 19% of patients 
with SES, and 23% of patients with PES up to three years (Figure 1, 
panel A). The hazard ratio (HR) was 1.00 comparing TiNOX stents 
with SES (95% CI 0.69-1.45, p=1.00), and 0.95 comparing TiNOX 
stents with PES (95% CI 0.66-1.36, p=0.78) (Table 4). A sensitivity 
analysis of the primary outcome up to three years adjusted for all 
procedural characteristics and discharge medications yielded simi-
lar results (TiNOX vs. SES: HR 1.08, 95% CI 0.62-1.89, p=0.79; 
TiNOX vs. PES: HR 1.26, 95% CI 0.76-2.07, p=0.37).
Rates of death, TLR, and TVR were similar between groups, 
with hazard ratios around 1 and confidence intervals compatible 
with both, substantial advantages or disadvantages of the TiNOX 
stent over the drug-eluting stents (Table 4 and Figure 1, panels B, 
D and E). MI and stent thrombosis tended to be less frequent in 
patients treated with TiNOX stents as compared with SES or PES, 
with hazard ratios between 0.33 and 0.63 (Table 4), but confidence 
intervals were wide and overlapped the null effect at 1 (p ≥0.18).
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discussion
In these propensity-matched analyses, long-term clinical outcomes 
after implantation of TiNOX-coated stents and first generation 
drug-eluting stents (SES or PES) were similar for the three stent 
types. Hazard ratios for MACE, the composite primary outcome of 
death overall, myocardial infarction, or TVR were approximately 
one in both comparisons (TiNOX versus SES and TiNOX versus 
PES). There was a slight trend towards lower MI and stent throm-
bosis rates in patients treated with TiNOX stents compared to 
patients treated with SES or PES, but confidence intervals were 
wide and differences non-significant.
Our study has several limitations. It was not a randomised com-
parison between TiNOX stents and SES or PES, and therefore the 
results may be biased. However, we used appropriate propensity-
score matching to ensure comparability of groups. Differences in 
procedural characteristics and co-medications initiated after stent 
implantation were observed, but by definition cannot be accounted 
for in a propensity matched analysis since these variables were 
Table 4. Clinical outcome in the propensity-score-matched groups.
tinOX SES Hazard	ratio	
(95%	cI) p-value
tinOX PES Hazard	ratio	
(95%	cI) p-valuetotal 319 319 337 337
Events up to 30 days (n [%])
MACE (death, MI, or TVR) 13 (4.1) 11 (3.5) 1.09 (0.48-2.47) 0.84 13 (3.9) 14 (4.2) 0.86 (0.40-1.85) 0.70
Death overall 7 (2.2) 6 (1.9) 1.17 (0.39-3.47) 0.78 7 (2.1) 9 (2.7) 0.78 (0.29-2.09) 0.62
Myocardial infarction 1 (0.3) 5 (1.6) 0.20 (0.02-1.71) 0.22* 1 (0.3) 3 (0.9) 0.33 (0.03-3.20) 0.62*
TLR 2 (0.6) 0 (0) 5.0 (0.24-103.7) 0.50* 2 (0.6) 4 (1.2) 0.50 (0.09-2.73) 0.69*
TVR 5 (1.6) 0 (0) 11.0 (0.61-198.1) 0.06* 5 (1.5) 5 (1.5) 1.00 (0.29-3.45) 1.00*
Stent thrombosis 1 (0.3) 0 (0) 3.0 (0.12-73.4) 1.00* 1 (0.3) 4 (1.2) 0.25 (0.03-2.24) 0.37*
Events up to 3-years (n [%])
MACE (death, MI, or TVR) 64 (20.1) 62 (19.4) 1.00 (0.69-1.45) 1.00 67 (19.9) 76 (22.6) 0.95 (0.66-1.36) 0.78
Death overall 27 (8.5) 26 (8.2) 1.04 (0.60-1.80) 0.89 28 (8.3) 33 (9.8) 0.93 (0.54-1.58) 0.79
Myocardial infarction 9 (2.8) 14 (4.4) 0.57 (0.24-1.36) 0.21 10 (3.0) 16 (4.8) 0.63 (0.28-1.38) 0.24
TLR 24 (7.5) 22 (6.9) 1.05 (0.58-1.88) 0.88 25 (7.4) 26 (7.7) 1.00 (0.57-1.76) 1.00
TVR 33 (10.3) 33 (10.3) 1.03 (0.63-1.71) 0.90 34 (10.1) 43 (12.8) 0.82 (0.51-1.31) 0.41
Stent thrombosis 2 (0.6) 6 (1.9) 0.33 (0.07-1.65) 0.18 2 (0.6) 5 (1.5) 0.40 (0.08-2.06) 0.27
Data are number of patients (percent). Hazard ratios are from Cox proportional hazard models. P-values are two-sided from superiority testing 
with a Wald test. Note that a continuity correction of 0.5 was used in case of zero events in one group. MI: myocardial infarction; TLR: target 
lesion revascularisation; TVR: target vessel revascularisation. * Fisher’s exact test
Table 3. Procedural and discharge characteristics after propensity score matching.
tinOX SES
p-value
tinOX PES
p-value
total 319 319 337 337
Procedural characteristics
Number of stents implanted (mean±SD) 1.52±0.82 1.72±0.89 0.002 1.51±0.81 1.73±0.95 0.001
Average stent diameter (mean±SD) 3.09±0.52 2.93±0.33 <0.001 3.09±0.52 2.96±0.34 <0.001
Total stent length (mean±SD) 25.3±15.7 32.5±18.7 <0.001 25.4±15.6 30.2±17.1 <0.001
Multivessel stenting (n [%]) 48 (15.1) 60 (18.8) 0.21 52 (15.4) 58 (17.2) 0.53
Saphenous vein graft intervention (n [%]) 1 (0.3) 10 (3.1) 0.006 1 (0.3) 8 (2.4) 0.02
Glycoprotein IIb/IIIa antagonists (n [%]) 50 (15.7) 101 (31.7) <0.001 54 (16.2) 113 (33.5) <0.001
Discharge medication
Acetylsalicylic acid (n [%]) 311 (97.5) 307 (96.2) 0.83 329 (97.6) 329 (97.6) 1.00
Clopidogrel (n [%]) 318 (99.7) 308 (96.6) 0.004 336 (99.7) 334 (99.1) 0.32
Oral anticoagulation (n [%]) 7 (2.2) 3 (0.9) 0.20 11 (3.3) 3 (0.9) 0.03
Beta blocker (n [%]) 264 (82.8) 168 (52.7) <0.001 281 (83.4) 207 (61.4) <0.001
ACE inhibitor (n [%]) 229 (71.8) 174 (54.6) <0.001 246 (73.0) 180 (53.4) <0.001
Statin (n [%]) 290 (90.9) 269 (84.3) 0.01 304 (90.2) 292 (86.7) 0.15
Values are expressed in n (%) or mean ± SD. Two-sided p-values were calculated using a chi-square test for categorical variables and an unpaired t-test 
for continuous variables. ACE inhibitor denotes angiotensin-converting enzyme inhibitor.
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Figure 1. Clinical outcomes in the propensity-score matched groups. The Kaplan-Meier curves show the cumulative incidence of the primary 
outcome (panel A), overall death (panel B), myocardial infarction (MI, panel C), target lesion revascularisation (TLR, panel D) and target 
vessel revascularisation (TVR, panel E) for up to 3-years. The comparison between TiNOX and SES is shown on the left, the comparison 
between TiNOX and PES on the right. p-values were calculated using the two-sided Wald tests derived from Cox proportional hazards models. 
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ascertained after treatment initiation and may be a reflection of the 
selected intervention11. The reason for the less frequent use of gly-
coprotein inhibitors in the TiNOX group is most likely related to 
a lower lesion complexity and to a higher proportion of TiNOX 
patients presenting with risk factors for bleeding or contraindica-
tions for glycoprotein inhibitors. To explain whether differences in 
procedural characteristics and co-medications could have influ-
enced the observed outcomes, we performed a sensitivity analysis 
adjusted for these variables and found results to be robust, again 
with no evidence to suggest superiority of the TiNOX stent over 
drug-eluting stents. Another limitation is the sequential enrolment 
period. It cannot be excluded that changes in treatment may have 
had a favourable impact on clinical outcome although treatment 
protocols did not change during enrolment at our institution. The 
durations of dual antiplatelet therapy with acetylsalicylic acid and 
clopidogrel were different between the three groups and could also 
have influenced the clinical outcomes. Patients treated with TiNOX 
stents had a median duration of dual antiplatelet therapy of three 
months as compared to 12 months observed for patients treated 
with drug-eluting stents. If a shorter duration of dual antiplatelet 
therapy in patients treated with TiNOX stents had a clinical effect, 
this would have resulted in more clinical events in patients receiv-
ing the TiNOX stent after termination of dual antiplatelet therapy. 
This would have put the TiNOX stent at a disadvantage in our 
study. A clear strength of this study is that we included unselected, 
consecutive patients. This notion is supported by the fact that one 
third of all included patients underwent primary PCI for ST-elevation 
MI (Tables 1 and 2). The findings may therefore be representative 
for patients encountered in routine clinical practice. Since there was 
no protocol-mandated angiographic follow-up, observed MACE 
rates are likely to reflect clinical decision making and management 
pathways at our centre.
Mechanisms of action are completely different between drug-
eluting and TiNOX-coated stents. In the first group the coating of 
the stent blocks cell regeneration in the G1 cycle, preventing pro-
liferation of smooth muscle cells and reducing restenosis within 
the stent. As a result, vascular healing is delayed and prevents in-
growth of stent struts partially or completely12-14. This lack of in-
growth and re-endothelialisation may be responsible for late and 
very late stent thrombosis15. In contrast, titanium-coated stents 
show rapid vascular healing within weeks or months. This has 
been attributed to the high corrosion resistance of the coating 
resulting in a high tissue compatibility with limited response to 
vessel injury. Platelet aggregation and fibrinogen binding has 
been shown to be reduced, resulting in a decreased rate of stent 
thrombosis and reduced neointimal growth1. Furthermore, the use 
of titanium nitride-oxide coating improves elasticity of the metal, 
minimising the risk of surface damages of the coating (cracks and 
splits of the coating). In addition, the titanium nitride-oxide forms 
nitric-oxide (NO) on the surface of the stent, which further 
reduces platelet aggregation and neointimal formation5. 
Considered together, titanium nitride-oxide coated stents show 
a favourable metal-tissue interaction with a comparable antipro-
liferative behaviour to the drug-eluting stents, but not at the 
expense of reduced vascular healing.
In a recently published propensity score adjusted analysis, 
Karjalainen et al found treatment with TiNOX stents to result in 
better long-term outcomes than PES. After three years of follow-up, 
the risk of MACE defined as the composite of cardiac death, MI, or 
TVR was 52% lower with TiNOX stents (adjusted HR 0.48, 95%-
CI 0.28-0.83)8. The registry-based nature of our study meant that 
we had to adhere to an alternate definition of MACE as the compos-
ite of death overall, MI or TVR. Since the overall death rate in 
patients with coronary artery disease is typically driven by cardiac 
deaths, we assumed a similar relative risk reduction for both defini-
tions, Karjalainen’s8 and ours. However, we failed to reproduce 
their findings, and found our results (HR of MACE 0.95, 95%-CI 
0.66-1.36) hardly compatible. In our view, methodological differ-
ences are the most likely explanation for the difference in results. In 
our analysis, we were careful in measuring a wide range of pre-
treatment variables that might confound comparisons of TiNOX 
with drug-eluting stents. In addition, we addressed the assumption 
of common support, which indicates that patients with the same 
propensity score must have a non-zero probability of receiving 
either TiNOX or one of the drug-eluting stents10. If probability den-
sities are too low in one of the groups, there is insufficient overlap 
of propensity scores and the assumption of common support is 
unlikely to be satisfied, and residual, unmeasured confounding may 
occur. Moreover, we used propensity score matching rather than 
conventional adjustment to further minimise confounding. Alternate 
explanations include the difference in endpoint definitions men-
tioned above and chance. Our results are compatible with short-
term results of randomised comparisons of TiNOX stents with PES 
in patients with acute myocardial infarction (the TITAX-AMI 
trial)16, and with a newer generation zotarolimus-eluting stent in 
patients with stable or unstable angina or non-ST-elevation MI7. In 
neither trial there was statistical evidence for a superiority of 
TiNOX stents over drug-eluting stents at 1-year: the RR of MACE 
versus PES was 0.78 in favour of TiNOX stents (95% CI 0.43 to 
1.43)16, the HR of MACE versus zotarolimus-eluting stents was 
1.19 in favour of zotarolimus-eluting stents (95% CI 0.71 to 2.00)7. 
Conversely, the 2-year follow-up of the TITAX-AMI trial sug-
gested a lower rate of MACE in the TiNOX stent group compared 
with the PES group (HR 0.45, 95% CI 0.26 to 0.77, p=0.004), 
which is somewhat at odds with our results17.
In conclusion, we did not find evidence to suggest a superiority of 
TiNOX stents over SES or PES at three years. Clinical outcomes 
were similar across stent types, even though most confidence inter-
vals were wide and compatible with both, substantial advantages and 
disadvantages of TiNOX stents over SES or PES. The duration of 
dual antiplatelet therapy in patients who underwent implantation of a 
drug-eluting stent is established at six months or more18,19. In view of 
the reduced duration of dual antiplatelet therapy possibly required for 
the TiNOX stent, we suggest that TiNOX stents may be an alternative 
to drug-eluting stents, particularly in patients with relative or absolute 
contraindications to prolonged dual antiplatelet therapy.
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